Drug Trial Radar · NCT04015518
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Jul 31, 2019
Primary completion
Aug 6, 2020
Study completion Jul 28, 2021
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16. The target dose(s) will be estimated from the model by incorporating information on the minimum clinically relevant effect and accounting for safety. Supportive dose-ranging assessments will also be done on pre-specified secondary endpoints.
Conditions
- Palmoplantar Pustulosis (PPP)
Interventions
SpesolimabDrug
Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
PlaceboDrug
Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
SpesolimabDrug
Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
SpesolimabDrug
Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
SpesolimabDrug
Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
SpesolimabDrug
Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage Change in Palmoplantar Pustulosis Area and Severity Index (PPP ASI) at Week 16 From BaselineTime frame: week 0 (baseline) and week 16
Locations
88 sites in 15 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama
Wallace Medical Group
Beverly Hills, California
Therapeutics Clinical Research
San Diego, California
Advanced Medical Research PC
Sandy Springs, Georgia
Epiphany Dermatology of Kansas, LLC
Overland Park, Kansas
University of Missouri Health System
Columbia, Missouri
Washington University School of Medicine
St Louis, Missouri
Skin Specialists, P.C.
Omaha, Nebraska
The Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Paddington Testing Co., Inc.
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Menter Dermatology Research Institute
Dallas, Texas
University of Utah Health
Murray, Utah
Virginia Clinical Research, Inc.
Norfolk, Virginia
Paratus Clinical Research Woden
Phillip, Australian Capital Territory, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Veracity Clinical Research
Wooloongabba, Queensland, Australia
Skin Health Institute Inc
Carlton, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Brussels - UNIV Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
CARe Clinic
Red Deer, Alberta, Canada
Dr. Irina Turchin PC Inc.
Fredericton, New Brunswick, Canada
SimcoDerm Medical and Surgical Dermatology Centre
Barrie, Ontario, Canada
The Guenther Dermatology Research Centre
London, Ontario, Canada
York Dermatology Clinic and Research Centre
Richmond Hill, Ontario, Canada
K. Papp Clinical Research Inc.
Waterloo, Ontario, Canada
Innovaderm Research Inc.
Montreal, Quebec, Canada
CCBR Czech a.s.
Pardubice, Czechia
Sanatorium Prof. Arenebergera
Prague, Czechia
CCBR Czech Prague s.r.o.
Prague, Czechia
HOP l'Archet
Nice, France
HOP Saint-Louis
Paris, France
HOP Larrey
Toulouse, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, Germany
CRU Hungary Ltd, Private Practice, Miskolc
Miskolc, Hungary
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.